SCHEMBL4221963

SCHEMBL4221963

O=C(O)c1ccc(-c2ccccc2OC(F)(F)F)cc1Nc1ccc(F)cc1

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
DHODH Q02127 1/20 0.49
FABP4 P15090 1/20 0.47
FABP5 Q01469 1/20 0.47
AKR1C3 P42330 3/20 0.43
AKR1C2 P52895 3/20 0.43
FFAR4 Q5NUL3 1/20 0.43
RORC P51449 2/20 0.42
IDO1 P14902 2/20 0.42
CDC7 O00311 1/20 0.41
DAPK3 O43293 1/20 0.41
PAK4 O96013 1/20 0.41
PIM1 P11309 1/20 0.41
CDK2 P24941 1/20 0.41
FLT3 P36888 1/20 0.41
GSK3B P49841 1/20 0.41
CDK9 P50750 1/20 0.41
CDK5 Q00535 1/20 0.41
DYRK1A Q13627 1/20 0.41
MELK Q14680 1/20 0.41
MINK1 Q8N4C8 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4221155 0.86 AKR1C3 (0.54) DHODHAKR1C3AKR1C2ACLYCTSV
SCHEMBL4222586 0.83 AKR1C3 (0.45) DHODHAKR1C3AKR1C2IDO1CDC7
SCHEMBL4213652 0.83 ACMSD (0.55) DHODHFABP4AKR1C3AKR1C2CDC7
SCHEMBL4223552 0.82 AKR1C2 (0.50) DHODHAKR1C3AKR1C2IDO1AURKA
SCHEMBL4222916 0.82 XDH (0.49) DHODHFABP4AKR1C3AKR1C2CDC7
SCHEMBL4217609 0.82 DHODH (0.52) DHODHAKR1C3AKR1C2
SCHEMBL4212881 0.81 MCL1 (0.52) DHODHAKR1C3AKR1C2CDC7DAPK3
SCHEMBL4221487 0.81 PRSS12 (0.50) DHODHFABP4AKR1C3AKR1C2CDC7
SCHEMBL2275504 0.81 IGF2BP2 (0.56) DHODHACLY
SCHEMBL4215664 0.80 ACLY (0.52) FABP4AKR1C3AKR1C2CDC7DAPK3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8327467-B2 Anthranilic acid derivative or salt thereof TOYAMA CHEMICAL CO., LTD. (JP) 2012-12-11 US disclosed
EP-1860098-B1 NOVEL ANTHRANILIC ACID DERIVATIVE OR SALT THEREOF TOYAMA CHEMICAL CO LTD (JP) 2012-11-14 EP disclosed
US-20090105474-A1 NOVEL ANTHRANILIC ACID DERIVATIVE OR SALT THEREOF TOYAMA CHEMICAL CO., LTD. (JP) 2009-04-23 US disclosed
EP-1860098-A1 NOVEL ANTHRANILIC ACID DERIVATIVE OR SALT THEREOF TOYAMA CHEMICAL CO., LTD. (JP) 2007-11-28 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090105474-A1 NOVEL ANTHRANILIC ACID DERIVATIVE OR SALT THEREOF MMP13, MMP11, MMP3 DHODH 2975/4885FABP4 2976/4885FABP5 4296/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.